AOD-9604: The Weight Loss Peptide That Failed Phase III (And What to Do Instead)

What AOD-9604 Is

AOD-9604 is a synthetic peptide consisting of amino acids 176–191 of human growth hormone (the C-terminal fragment). The theory behind its development: GH has two distinct functional domains — a growth-promoting domain and a lipolytic (fat-burning) domain. By isolating just the lipolytic fragment, developers hoped to get fat loss without GH's growth-promoting and insulin-antagonizing effects.

In animal studies, the results were genuinely compelling: obese mice and rats given AOD-9604 showed significant fat reduction, faster than controls, without the weight gain or insulin resistance seen with full GH. This generated substantial investor interest and a promising early development pipeline.

The Clinical Trial Results

The Phase III trial — a 24-week, double-blind, randomized controlled trial in obese patients — showed no significant difference in weight loss between AOD-9604 and placebo. The drug failed its primary endpoint.

Subsequent analysis pointed to several likely explanations:

• Species translation failure: Rodent fat metabolism differs meaningfully from human fat metabolism. Compounds that work in mice frequently fail to translate to comparable human effects.
• Dosing uncertainty: The effective dose in humans may differ substantially from animal-derived extrapolations.
• GH receptor complexity: The lipolytic effect in humans may require more of the GH molecule's context than the isolated 176-191 fragment provides.

Following the Phase III failure, Metabolic Pharmaceuticals abandoned the obesity indication. AOD-9604 was later investigated for osteoarthritis (a different application entirely) but remains without approved indications.

Current Status and What People Use It For

Despite the Phase III failure, AOD-9604 remains popular in the supplement and research chemical market. Why? Several reasons:

• Marketing momentum — the "GH fragment" framing is compelling and widely repeated
• Anecdotal reports of mild fat loss effects that users attribute to the compound (though these are impossible to separate from placebo, diet changes, and concurrent interventions)
• The failed trial didn't prove it has zero effect — it proved the effect was not large enough to beat placebo in a controlled setting at tested doses

The honest assessment: AOD-9604 may have mild lipolytic activity in some individuals, but the evidence for meaningful fat loss is weak. People using it for weight management would likely see better results from GLP-1 peptides (semaglutide, tirzepatide) or tesamorelin (for visceral fat specifically), both of which have Phase III evidence.

What Actually Works Instead